Skip to content

ChronoScale

US · CHRN #2563 by market cap Listed 1970
19.77 +0.49 +2.54%
Live - 5344 symbols - heartbeat 295s ago · 2026-10-08 07:02
Pre-market 20.50 +3.69%
After-hours 20.00 +1.16%
Market cap
2.88B
P/B
16.00
EPS
-0.36
Reader sentiment Are you bullish or bearish on CHRN?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 15.60 Expensive vs history 91st percentile
5-year average 2.14 · #73 of 74 in Information Technology Services
P/E ratio -53.56 Cheap vs history 3rd percentile
5-year average -5.33
P/S ratio 39.21 Expensive vs history 96th percentile
5-year average 4.47 · forward 25.78 · #74 of 79 in Information Technology Services

Vs. peers Information Technology Services

Company Market cap P/E (TTM) P/B Div yield
ChronoScale (CHRN) 2.88B -54.92 16.00 0.00%
IBM Corp (IBM) 207.75B 19.53 6.03 3.05%
Accenture (ACN) 117.20B 14.50 3.71 3.32%
Infosys (INFY) 42.73B 13.02 4.44 4.97%
Cognizant (CTSH) 25.71B 12.25 1.78 2.24%
Fiserv (FISV) 24.09B 8.68 0.90 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value12.23 Economic moatNone UncertaintyVery High

Trading 38.2% above Morningstar's fair value estimate.

Fair value

ChronoScale Holdings Corp earns a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 53% premium over our quantitative fair value estimate of $12.23 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The company's valuation metrics weaken our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 105.8, which ranks in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's sales yield of 2.7%, a core component of profitability, ranks in the bottom 10% compared with peers globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 07:02:12 · For reference only, not investment advice and not tailored to your situation.